This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Elsevier Announces The Launch Of A New Open Access Journal: Urology Case Reports

LONDON, November 25, 2013 /PRNewswire/ --

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of a new open access journal: Urology Case Reports .

Urology Case Reports is a new peer-reviewed, open access journal dedicated to publishing case reports in all areas of adult and pediatric urology.

Surveys of practicing urologists have shown that the time available for them to read journals, medical newspapers and attend lectures for Continuing Medical Education (CME) is diminishing. Some studies note that the average time physicians can realistically spend on furthering their education is 15 minutes per week; what they choose to read during this limited time is now ever more important.

Urology Case Reports acknowledges these time constraints whilst at the same time fulfilling educational needs. Case reports published are short and frequently well illustrated with images that can "speak a thousand words".

Kate Williamson, Publisher for Urology Case Reports at Elsevier, explains: "Many journals in the field of urology no longer publish case reports, but the need for such an outlet remains. Authors want to publish interesting case reports, which can serve as a valuable learning tool for readers. Elsevier is proud to work with Editors Dr. Partin and Dr. Wein to provide this new resource for urologists."

Dr. Partin added, "A journal like this will greatly improve our ability to share unique, interesting and educational clinical anecdotes."

The first case report published in Urology Case Reports is now available to read online on ScienceDirect. The article describes a rare neoplasm which poses a therapeutic challenge to urologists who manage patients with this rare disease: " A Case Report of Primary Recurrent Malignant Melanoma of the Urinary Bladder"

For more information or to submit an article, go to Urology Case Reports:

About Open Access Publishing at Elsevier

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs